Microbot Medical (MBOT) Projected to Post Earnings on Wednesday

Key Points

• Microbot Medical is set to release its earnings data on August 13th, with analysts predicting an earnings per share (EPS) of ($0.08) for the quarter.
• In the last earnings report on May 21st, the company reported an EPS of ($0.08), exceeding the consensus estimate.
• The stock has seen recent institutional investment, with Goldman Sachs purchasing 37,744 shares in the first quarter, representing approximately 0.11% ownership of the company.

Microbot Medical (NASDAQ:MBOT - Get Free Report) is expected to be releasing its earnings data before the market opens on Wednesday, August 13th. Analysts expect Microbot Medical to post earnings of ($0.08) per share for the quarter.

Microbot Medical (NASDAQ:MBOT - Get Free Report) last posted its earnings results on Wednesday, May 21st. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.07. On average, analysts expect Microbot Medical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Microbot Medical Price Performance

MBOT opened at $2.88 on Wednesday. The business's 50-day moving average is $2.58 and its two-hundred day moving average is $2.19. Microbot Medical has a 1 year low of $0.82 and a 1 year high of $3.38. The firm has a market capitalization of $104.77 million, a PE ratio of -4.43 and a beta of 1.15.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Microbot Medical stock. Goldman Sachs Group Inc. purchased a new position in shares of Microbot Medical Inc. (NASDAQ:MBOT - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 37,744 shares of the biotechnology company's stock, valued at approximately $57,000. Goldman Sachs Group Inc. owned approximately 0.11% of Microbot Medical as of its most recent filing with the Securities & Exchange Commission. 16.30% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. HC Wainwright reiterated a "buy" rating and issued a $9.00 target price on shares of Microbot Medical in a research note on Thursday, April 10th. Wall Street Zen raised Microbot Medical from a "sell" rating to a "hold" rating in a report on Saturday, June 14th.

Microbot Medical Company Profile

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.